GENETICS INSTITUTE's BENEFIX LABEL SHOULD WARN OF PK DIFFERENCES FROM PLASMA- DERIVED FACTOR IX, ADVISORY CMTE. SAYS; SAFETY STUDIES TO CONTINUE IN PHASE IV
"An adjusted dosing algorithm and a prominent warning should be included in the package insert" for Genetics Institute's recombinant Factor IX BeneFix "to accommodate the observed differences in the recovery of plasma-derived coagulation Factor IX, human, and coagulation Factor IX, recombinant," FDA's Blood Products Advisory Committee agreed unanimously Dec. 12.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth